| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Sanofi | Capeserod | Gastrointestinal (GI) indications | Phase 2 | Trial Planned | Oral | Gastroenterology |
| Sanofi | VG-3927 | Alzheimer's disease | Phase 2 | Trial Planned | Oral | Neurology |
| Sanofi | SAR4442454, BNT111 and LIBTAYO (cemiplimab) | Melanoma | Phase 2 | Data Released | SAR4442454: Intravenous BNT111: Intravenous LIBTAYO (cemiplimab): Intravenous | Oncology |
| Sanofi | VGL101 - (ILLUMINATE) | Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) | Phase 2 | Ongoing | Intravenous | Neurology |
| Sanofi | Amcenestrant - (AMEERA-3) | Breast Cancer | Phase 2 | Trial Completed | Oral | Oncology |
| Sanofi | Pegenzileukin (THOR-707) and KEYTRUDA (pembrolizumab) | Solid tumors | Phase 2 | Ongoing | Intravenous | Oncology |
| Sanofi | KT-474 (SAR444656) - (ADVANTA) | Hidradenitis suppurativa / atopic dermatitis | Phase 2 | Trial Discontinued | oral | Immunology |
| Sanofi | DNL788 (SAR443820) | Multiple sclerosis | Phase 2 | Trial Discontinued | Oral | Neurology |